bisoprolol has been researched along with Coronary Heart Disease in 29 studies
Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| ") injection of bisoprolol in patients with coronary heart disease." | 9.08 | [Coronary sinus blood flow after intracoronary or intravenous administration of bisoprolol in coronary disease]. ( Fleuchaus, M; Gonschior, P; Höfling, B; Larisch, K; Stäblein, A, 1995) |
| "Twelve patients with stable angina pectoris due to coronary heart disease received single oral doses of 5, 10, and 20 mg bisoprolol in a placebo-controlled double-blind crossover study." | 9.06 | Effect of bisoprolol on exercise tolerance in patients with coronary heart disease: placebo-controlled double-blind crossover study. ( Marsovszky, E; Roskamm, H; Schnellbacher, K, 1986) |
| "The effects of 5 and 10 mg bisoprolol once daily for 7 days on exercise ECG, myocardial perfusion and left ventricular function in 25 patients with stable coronary heart disease have been assessed in a double-blind, randomized, parallel group trial design." | 9.06 | Effect of bisoprolol on cardiac performance in coronary heart disease. ( Borst, U; Gerhards, W; Maisch, B; Wagner, G, 1989) |
| "The effects of single, consecutively increased, oral doses of the beta-adrenoceptor antagonist bisoprolol (5, 10, 15, 20, 30 and 40 mg) on blood pressure, heart rate and bronchomotor tone were investigated in an open acute trial with 16 patients suffering from angina pectoris due to coronary heart disease and reversible chronic obstructive bronchitis." | 7.67 | Dose-response relationship of the beta-adrenoceptor antagonist bisoprolol in patients with coronary heart disease and chronic obstructive bronchitis. ( Dorow, P; Tönnesmann, U, 1984) |
| "This report summarizes the most important results of 11 studies regarding efficacy and safety of bisoprolol in patients with stable angina pectoris due to coronary heart disease." | 7.67 | Summary of short- and long-term studies with bisoprolol in coronary heart disease (CHD). ( Wagner, G, 1986) |
| "The authors performed a double-blinded, placebo-controlled, multicenter trial to compare the effect of bisoprolol with that of placebo on 1-yr composite outcome including cardiovascular mortality, nonfatal myocardial infarction, unstable angina, congestive heart failure, and cerebrovascular insult." | 5.12 | Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: the Swiss Beta Blocker in Spinal Anesthesia (BBSA) study: a double-blinded, placebo-contro ( Bestmann, L; Blumenthal, S; Boltres, A; Borgeat, A; Furrer, L; Hersberger, M; Hofer, C; Kälin, G; Lucchinetti, E; Müller, A; Schulz, C; Spahn, DR; Wacker, J; Zaugg, M; Zollinger, A, 2007) |
| ") injection of bisoprolol in patients with coronary heart disease." | 5.08 | [Coronary sinus blood flow after intracoronary or intravenous administration of bisoprolol in coronary disease]. ( Fleuchaus, M; Gonschior, P; Höfling, B; Larisch, K; Stäblein, A, 1995) |
| "Twelve patients with stable angina pectoris due to coronary heart disease received single oral doses of 5, 10, and 20 mg bisoprolol in a placebo-controlled double-blind crossover study." | 5.06 | Effect of bisoprolol on exercise tolerance in patients with coronary heart disease: placebo-controlled double-blind crossover study. ( Marsovszky, E; Roskamm, H; Schnellbacher, K, 1986) |
| "The effects of 5 and 10 mg bisoprolol once daily for 7 days on exercise ECG, myocardial perfusion and left ventricular function in 25 patients with stable coronary heart disease have been assessed in a double-blind, randomized, parallel group trial design." | 5.06 | Effect of bisoprolol on cardiac performance in coronary heart disease. ( Borst, U; Gerhards, W; Maisch, B; Wagner, G, 1989) |
| "The effects of single, consecutively increased, oral doses of the beta-adrenoceptor antagonist bisoprolol (5, 10, 15, 20, 30 and 40 mg) on blood pressure, heart rate and bronchomotor tone were investigated in an open acute trial with 16 patients suffering from angina pectoris due to coronary heart disease and reversible chronic obstructive bronchitis." | 3.67 | Dose-response relationship of the beta-adrenoceptor antagonist bisoprolol in patients with coronary heart disease and chronic obstructive bronchitis. ( Dorow, P; Tönnesmann, U, 1984) |
| "This report summarizes the most important results of 11 studies regarding efficacy and safety of bisoprolol in patients with stable angina pectoris due to coronary heart disease." | 3.67 | Summary of short- and long-term studies with bisoprolol in coronary heart disease (CHD). ( Wagner, G, 1986) |
| "Type 2 diabetes is becoming very common and is closely linked to physical inactivity and obesity." | 2.41 | Beta-blockers and diabetes: the bad guys come good. ( Cruickshank, JM, 2002) |
| "A randomised, open-label, two-period, crossover, single-dose, relative bioavailability study was conducted in fasted healthy Caucasian volunteers." | 1.46 | Bioequivalence study of 2.5 mg film-coated bisoprolol tablets in healthy volunteers. ( Bielak, A; Buś-Kwaśnik, K; Ksycińska, H; Leś, A; Płatek, AE; Raszek, J; Rudzki, PJ; Serafin-Byczak, K; Szymański, FM; Wybraniec, A; Łazowski, T, 2017) |
| "Indications for treatment were hypertension (75%), coronary artery disease with (12%) or without (3%) hypertension, or unknown (10%)." | 1.30 | Beta adrenergic blockers lower renin in patients treated with ACE inhibitors and diuretics. ( Danser, AH; Hense, HW; Holmer, SR; Mayer, B; Riegger, GA; Schunkert, H, 1998) |
| "Bisoprolol appears to be a very potent beta-blocker that is well tolerated at an intravenous dose of 10 mg." | 1.28 | Study of the electrophysiological properties of intravenous bisoprolol in patients with and without coronary artery disease by programmed stimulation. ( Bricaud, H; Clémenty, J; Coste, P; Samoyeau, R, 1990) |
| "Bisoprolol was devoid of affinity for autonomic receptors other than beta-adrenoceptors or for autacoid receptors." | 1.27 | High beta 1-selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol. ( Becker, KH; Bergmann, R; Enenkel, HJ; Haeusler, G; Klockow, M; Minck, KO; Schelling, P; Schliep, HJ; Schmitges, CJ; Schulze, E, 1986) |
| "Bisoprolol was given orally to 16 patients, six receiving 5 mg, and 10 patients receiving 20 mg." | 1.27 | Effects of bisoprolol in relation to metoprolol and bufuralol on left ventricular hemodynamics at rest and during exercise in chronic ischemic heart disease. ( Burkart, F; Pfisterer, M; Steinmann, E, 1986) |
| "Bisoprolol was about 2 times more effective in suppressing isoprenaline-induced increases in LVdP/dtmax than those in heart rate." | 1.27 | Bisoprolol improves perfusion of ischaemic myocardium in anaesthetized pigs. ( den Boer, MO; Rensen, RJ; Sassen, LM; Saxena, PR; Verdouw, PD, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (41.38) | 18.7374 |
| 1990's | 9 (31.03) | 18.2507 |
| 2000's | 5 (17.24) | 29.6817 |
| 2010's | 3 (10.34) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buś-Kwaśnik, K | 1 |
| Rudzki, PJ | 1 |
| Ksycińska, H | 1 |
| Leś, A | 1 |
| Serafin-Byczak, K | 1 |
| Raszek, J | 1 |
| Bielak, A | 1 |
| Wybraniec, A | 1 |
| Płatek, AE | 1 |
| Szymański, FM | 1 |
| Łazowski, T | 1 |
| Tarlovskaya, EI | 1 |
| Chudinovskih, TI | 1 |
| Waqar, S | 1 |
| Sarkar, PK | 1 |
| Minushkina, LO | 1 |
| Cruickshank, JM | 1 |
| Patel, MR | 1 |
| Gattis, W | 1 |
| Zaugg, M | 1 |
| Bestmann, L | 1 |
| Wacker, J | 1 |
| Lucchinetti, E | 1 |
| Boltres, A | 1 |
| Schulz, C | 1 |
| Hersberger, M | 1 |
| Kälin, G | 1 |
| Furrer, L | 1 |
| Hofer, C | 1 |
| Blumenthal, S | 1 |
| Müller, A | 1 |
| Zollinger, A | 1 |
| Spahn, DR | 1 |
| Borgeat, A | 1 |
| Dorow, P | 2 |
| Tönnesmann, U | 1 |
| Prager, G | 2 |
| Wagner, G | 3 |
| Gonschior, P | 1 |
| Fleuchaus, M | 1 |
| Larisch, K | 1 |
| Stäblein, A | 1 |
| Höfling, B | 1 |
| Günnicker, M | 1 |
| Freund, U | 1 |
| Grebe, EJ | 1 |
| Scherer, R | 1 |
| Schieffer, M | 1 |
| Zerkowski, HR | 1 |
| Hess, W | 1 |
| Holmer, SR | 1 |
| Hense, HW | 1 |
| Danser, AH | 1 |
| Mayer, B | 1 |
| Riegger, GA | 1 |
| Schunkert, H | 1 |
| Weber, F | 1 |
| Schneider, H | 1 |
| von Arnim, T | 1 |
| Urbaszek, W | 1 |
| Poole-Wilson, PA | 1 |
| Clémenty, J | 1 |
| Samoyeau, R | 1 |
| Coste, P | 1 |
| Bricaud, H | 1 |
| Jenkins, NP | 1 |
| Keevil, BG | 1 |
| Hutchinson, IV | 1 |
| Brooks, NH | 1 |
| van den Ende, R | 1 |
| Batink, HD | 1 |
| Pfaffendorf, M | 1 |
| van Zwieten, PA | 1 |
| Graffius, D | 1 |
| Eichwede, F | 1 |
| Komar, K | 1 |
| Müller, R | 1 |
| Grote, B | 1 |
| Tarnow, J | 1 |
| Schnellbacher, K | 1 |
| Marsovszky, E | 1 |
| Roskamm, H | 1 |
| Haeusler, G | 1 |
| Schliep, HJ | 1 |
| Schelling, P | 1 |
| Becker, KH | 1 |
| Klockow, M | 1 |
| Minck, KO | 1 |
| Enenkel, HJ | 1 |
| Schulze, E | 1 |
| Bergmann, R | 1 |
| Schmitges, CJ | 1 |
| Burkart, F | 1 |
| Pfisterer, M | 1 |
| Steinmann, E | 1 |
| Bonelli, J | 1 |
| Staribacher, H | 1 |
| Prager, W | 1 |
| Hönig, B | 1 |
| Maisch, B | 1 |
| Borst, U | 1 |
| Gerhards, W | 1 |
| Ogawa, T | 1 |
| Hieda, N | 1 |
| Sugiyama, S | 1 |
| Ito, T | 1 |
| Satake, T | 1 |
| Ozawa, T | 1 |
| Sassen, LM | 1 |
| den Boer, MO | 1 |
| Rensen, RJ | 1 |
| Saxena, PR | 1 |
| Verdouw, PD | 1 |
2 reviews available for bisoprolol and Coronary Heart Disease
| Article | Year |
|---|---|
[Bisoprolol: opportunities in the treatment of hypertension].
Topics: Adrenergic beta-1 Receptor Antagonists; Biological Availability; Bisoprolol; Comorbidity; Coronary D | 2012 |
Beta-blockers and diabetes: the bad guys come good.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Bisoprolol; Coronary Disease; Diabet | 2002 |
8 trials available for bisoprolol and Coronary Heart Disease
| Article | Year |
|---|---|
Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: the Swiss Beta Blocker in Spinal Anesthesia (BBSA) study: a double-blinded, placebo-contro
Topics: Adrenergic beta-Antagonists; Anesthesia, Spinal; Bisoprolol; Cardiomyopathy, Dilated; Cardiovascular | 2007 |
[Effect of bisoprolol in coronary heart disease. Effect on cardiovascular parameters and ischemic ST depression: studies on the duration of the effect].
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Bisoprolol; Clinical Trials as Topic; Coronary D | 1984 |
[Coronary sinus blood flow after intracoronary or intravenous administration of bisoprolol in coronary disease].
Topics: Aged; Bisoprolol; Blood Pressure; Coronary Circulation; Coronary Disease; Coronary Vessels; Data Int | 1995 |
Heart rate variability and ischaemia in patients with coronary heart disease and stable angina pectoris; influence of drug therapy and prognostic value. TIBBS Investigators Group. Total Ischemic Burden Bisoprolol Study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Bisoprolol; Calcium Channel Blockers; Cir | 1999 |
[New specialty drugs registered in Austria. Concor].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Austria; Bisoprolol; Clinical Trials as Topic; Coronar | 1990 |
[Preoperative treatment with beta-receptor blockers and isoflurane anesthesia. Hemodynamic interactions in patients with coronary disease].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anesthesia, Inhalation; Atenolol; Bisoprolol; Coronary Dis | 1990 |
Effect of bisoprolol on exercise tolerance in patients with coronary heart disease: placebo-controlled double-blind crossover study.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Clinical Trials as Topic; Coronary Disease; Dose-Response R | 1986 |
Effect of bisoprolol on cardiac performance in coronary heart disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Bisoprolol; Blood Pressure; Coronary Circ | 1989 |
19 other studies available for bisoprolol and Coronary Heart Disease
| Article | Year |
|---|---|
Bioequivalence study of 2.5 mg film-coated bisoprolol tablets in healthy volunteers.
Topics: Adolescent; Adult; Biological Availability; Bisoprolol; Chromatography, Liquid; Coronary Disease; Cr | 2017 |
[Comparative Prospective Clinical Economic Study of Original and Generic Bisoprolol in Patients With Coronary Heart Disease].
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Coronary Disease; Exercise Test; Female; Heart Rate; | 2016 |
Exacerbation of psoriasis with beta-blocker therapy.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Calcium; Coronary Artery Bypass; Coronary Disease; Follow-U | 2009 |
Which beta-blocker for heart failure?
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Contraindications; Coronary Disease | 2004 |
Dose-response relationship of the beta-adrenoceptor antagonist bisoprolol in patients with coronary heart disease and chronic obstructive bronchitis.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Airway Resistance; Bisoprolol; Blood Pressure; Bronchitis; | 1984 |
[Effect of dopexamine on the hemodynamics of coronary surgery patients with and without bisoprolol blockade].
Topics: Adrenergic beta-Agonists; Adult; Aged; Bisoprolol; Cardiac Output, Low; Coronary Artery Bypass; Coro | 1993 |
Beta adrenergic blockers lower renin in patients treated with ACE inhibitors and diuretics.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Bisoprolol; C | 1998 |
The Cardiac Insufficiency Bisoprolol Study II.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Coronary Disease; Heart Failure; Humans | 1999 |
Study of the electrophysiological properties of intravenous bisoprolol in patients with and without coronary artery disease by programmed stimulation.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Atrioventricular Node; Bisoprolol; Blood Pr | 1990 |
Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Atenolol; Bisoprolol; Body Mass Index; C-Reactive Protein; Cholesterol, | 2002 |
Discrepancies between inotropic responses and beta-adrenoceptor characteristics after global ischemia in isolated hearts.
Topics: Adrenergic alpha-Antagonists; Animals; Bisoprolol; Blood Pressure; Coronary Disease; Guinea Pigs; He | 1991 |
Summary of short- and long-term studies with bisoprolol in coronary heart disease (CHD).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Bisoprolol; Blood Pressure; Coronary Disease; Electrocardi | 1986 |
High beta 1-selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol.
Topics: Adrenergic beta-Antagonists; Anesthesia; Anesthetics, Local; Animals; Bisoprolol; Blood Vessels; Cat | 1986 |
Beta 1/beta 2-splitting of bisoprolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Airway Resistance; Bisoprolol; Blood Pressure; Coronary Di | 1986 |
Effects of bisoprolol in relation to metoprolol and bufuralol on left ventricular hemodynamics at rest and during exercise in chronic ischemic heart disease.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Coronary Circulation; Coronary Disease; Ethanolamines; Hear | 1986 |
Haemodynamic effects of bisoprolol in patients with coronary heart disease: influence of various bisoprolol plasma concentrations.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Bisoprolol; Coronary Disease; Hemodynamics; Humans; Middle | 1986 |
Effect of beta-adrenergic blockade on the circadian rhythm of myocardial ischemia in ambulatory patients with stable angina.
Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care; Angina Pectoris; Bisoprolol; Circadian Rhythm; C | 1989 |
Cardioprotective and antiarrhythmic effects of beta-blockers, propranolol, bisoprolol, and nipradilol in a canine model of regional ischemia.
Topics: Acetylglucosaminidase; Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Bisoprolol; Coron | 1989 |
Bisoprolol improves perfusion of ischaemic myocardium in anaesthetized pigs.
Topics: Anesthesia; Animals; Arrhythmias, Cardiac; Bisoprolol; Coronary Circulation; Coronary Disease; Hemod | 1988 |